Another approach to overcome the loss of the antigen was invented by scientists from the United States and China who developed second generation CAR T-cells against another marker of B-specific cells, namely the B-cell activating factor receptor (BAFF-R), a target for cancer immunotherapy, which is not yet fully implemented [237]. The gene discussed is TNFRSF13C; the disease is cancer.